1228561-05-4

Usage

Uses

Used in Pharmaceutical Synthesis:
(R)-1-AMINO-INDAN-4-OL is used as a key intermediate for the development of pharmaceuticals targeting a range of medical conditions. Its unique structural and stereochemical features enable the creation of novel drug candidates with improved efficacy and selectivity.
Used in Organic Chemistry:
As a building block in organic chemistry, (R)-1-AMINO-INDAN-4-OL is used for the synthesis of various complex organic molecules. Its chiral nature allows for the development of enantiomerically pure compounds, which are essential in many biological and pharmaceutical applications.
Used in Drug Development:
(R)-1-AMINO-INDAN-4-OL is employed as a starting material in the development of new drugs for the treatment of various medical conditions. Its potential applications in this field are vast, as it can be modified and functionalized to create a diverse array of therapeutically relevant compounds.
Used in Research and Development:
In the realm of research and development, (R)-1-AMINO-INDAN-4-OL serves as a valuable tool for exploring new compounds with therapeutic properties. Its unique structural features make it an ideal candidate for studying the structure-activity relationships of potential drug candidates and for identifying novel pharmacological targets.
Overall, (R)-1-AMINO-INDAN-4-OL is a versatile and important compound in the fields of medicinal chemistry, pharmaceutical synthesis, and drug development, with a wide range of applications and potential for further exploration.

Upstream product

• 103441-70-9 4-hydroxy-indan-1-one oxime 
• 40731-98-4 4-hydroxy-2,3-dihydroindan-1-one 
• 103441-70-9 4-hydroxy-indan-1-one oxime 

Downstream Products

• 1201362-27-7 2-anilino-7-[(1S)-4-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 

Relevant academic research and scientific papers

5,7-DIHYDRO-6H-PYRROLO[2,3-D]PYRIMIDIN-6-ONE DERIVATIVES FOR MARK INHIBITION

Compounds of formula I: are potent and selective inhibitors of microtubule affinity regulating kinase (MARK), and hence find use in treatment of Alzheimer's disease and other conditions associated with hyperphosphorylation of tau.

Hydroxy-1-aminoindans and derivatives: Preparation, stability, and reactivity

The chemical stability and reactivity of hydroxy-1-aminoindans and their N-propargyl derivatives are strongly affected by the position of the OH group and its orientation relative to that of the amino moiety. Thus, the 4- and 6-OH regioisomers were found to be stable, while the 5-OH analogues were found to be inherently unstable as the free bases. The latter, having a para orientation between the OH and the amino moieties, could be isolated only as their hydrochloride salts. 7-Hydroxy-1-aminoindans and 7-hydroxy-1- propargylaminoindans represent an intermediate case; while sufficiently stable even as free bases, they exhibit, under certain experimental conditions, unexpected reactivity. The instability of the 5- and 7-hydroxy-aminoindans is attributed to their facile conversion to the corresponding, reactive quinone methide (QM) intermediates. The o-QM obtained from 7-hydroxy-aminoindans was successfully trapped with ethyl vinyl ether via a Diels-Alder reaction to give tricyclic acetals 32a,b.

Novel Cerebroprotective Agents with Central Nervous System Stimulating Activity. 1. Synthesis and Pharmacology of 1-Amino-7-hydroxyindan Derivatives

To developed a novel cerebroprotective agent with central nervous system (CNS) stimulating activity, a series of 1-amino-7-hydroxyindan derivatives was synthesized, and their effects on the survival time of mice under hypoxic conditions were tested.CNS-stimulating activity was also evaluated by examining the promotional effect on the recovery from cerebral concussion induced coma in mice.Several compounds prolonged the survival time of mice in hypoxic conditions at a dose of 30 mg/kg (sc or ip) and 100 mg/kg (po).They also exhibited the promotional effects on recovery from coma at a dose of 100 mg/kg po.The three most potent compounds in both tests, 1-amino-7-hydroxy-6-(1-methylpropyl)indan (20), 1-amino-7-hydroxy-4,6-dimethyl-2-phenylindan (30), and 1-amino-7-hydroxy,2,2,4,6-tetramethylindan (35) were selected for further investigations.Structure-activity relationships were also discussed.